Tenderwize
Retour à la recherche

Open-house rebate agreement for Ublituximab

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Feb 28, 2027 · 131 days left·Open·Supplies
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Ublituximab, ATC L04AG14

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

Submission by original document is required and electronic submission is not allowed, which increases the risk of late...

The buyer reserves the right to replace the open-house contracts with exclusive rebate agreements during the term, whic...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse
Pays
Allemagne
CPV
33600000 - Pharmaceutical products
Date limite
Feb 28, 2027

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Non-exclusive rebate agreements for pharmaceutical products containing Ublituximab (ATC L04AG14).
  • Open-house model with uniform conditions for all participants and no individual negotiations.
Afficher le résumé complet

Open-house supply arrangement for the active substance Ublituximab (ATC L04AG14) offered by AOK Rheinland-Pfalz/Saarland. It is a non-exclusive, no-selection contract model with uniform terms for all participants, no individual negotiations, and monthly entry possible during the 24-month term. The notice states that this publication is not a public contract in the sense of procurement law, but it is published in TED for transparency. No contract value is provided.

Risques

Submission by original document is required and electronic submission is not allowed, which increases the risk of late...

The buyer reserves the right to replace the open-house contracts with exclusive rebate agreements during the term, whic...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Only authorised and legally marketable medicines in Germany may be supplied.

Administrative

  • If a medicine is not yet listed in Lauer-Taxe at submission time, an AMIce public extract must be provided.
  • The AMIce extract must show name, marketing authorisation holder or authorised manufacturer, dosage form, active substance, and marketability.

Acheteur

Localisation

Eisenberg, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE271900642

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreement for Ublituximab

Single lot covering non-exclusive pharmaceutical rebate agreements for medicines containing Ublituximab. The open-house model applies uniform terms to all participating pharmaceutical companies. Children’s medicines listed in the BfArM list under Section 35(5a) SGB V are excluded. Contract start is earliest 2025-05-01, with monthly entry possible during the 24-month period; contracts end no later than 24 months after the earliest start date. The lot information comes from structured data and the TED XML notice.

SuppliesEU fundedElectronic submission

Localisation

Eisenberg, Germany

Durée

Apr 2025 - Apr 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 28, 2027

Détails de la procédure

Date de publication
26 Mar 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
196730-2025

Documents (1)

Appels d'offres similaires